References
- Hellgren L. Association between rheumatoid arthritis and psoriasis in total populations. Acta Rheumatol Scand 1969; 15(4): 316–26
- Baker H. Epidemiological aspects of psoriasis and arthritis. Br J Dermatol 1966; 78(5): 249–61
- Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3(l): 55–78
- Helliwell P, Marchesoni A, Peters M, et al. A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 1991; 30(5): 339–45
- Wright V, Moll JM, eds. Seronegative polyarthritis. Amsterdam: North-Holland Pub, 1976
- Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis 1976; 35(4): 354–6
- Rosenberg EW, Noah PW, Wyatt RJ, et al. Complement activation in psoriasis. Clin Exp Dermatol 1990; 15(l): 16–20
- Gladman DD. Immunologic factors in the pathogenesis of psoriatic arthritis. In: Gerber LH, Espinoza LR, eds. Psoriatic arthritis. Orlando, Fia: Grune & Stratton, 1985: 33
- Torre Alonso JC, Perez AR, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. BrJ Rheumatol 1991; 30(4): 245–50
- al-Jarallah KF, Singal DP, Buchanan WW. Immunogenetics of psoriatic arthritis. Immunol Invest 1993; 22(2): 81–6
- Li F, Nanagara R, Rothfuss S, et al. Demonstration of peptidoglycan in synovial fluid cells as a possible arthritogenic factor in psoriatic arthritis. (Abstr) Arthritis Rheum 1994; 37(9): S204
- Espinoza LR, Vasey FB, Espinoza CG, et al. Vascular changes in psoriatic synovium: a light and electron microscopic study. Arthritis Rheum 1982; 25(6): 677–84
- Veale D, Yanni G, Rogen S, et al. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993; 36(7): 893–900
- Farr M, Kitas GD, Waterhouse L, et al. Sulphasalazine in psoriatic arthriris: a doubleblind placebo-controlled study. Br J Rheumatol 1990; 29(l): 46–9
- Black RL, O'Brien WM, Van Scott EJ, et al. Methotrexate therapy in psoriatic arthritis, double-blind study on 21 patients. JAMA 1964; 189(Sept7): 743–7
- Dorwart BB, Gall EP, Schumacher HR, et al. Chrysotherapy in psoriatic arthritis: efficacy and toxicity compared to rheumatoid arthritis. Arthritis Rheum 1978; 21(5): 513–5
- Gupta AK, Matteson EL, Ellis CN, et al. Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 1989; 125(4): 507–10
- Price R, Gibson T. D-penicillamine and psoriatic arthropathy. (Letter) Br J Rheumatol 1986; 25(2): 228
- Gladman DD, Blake R, Brubacher B, et al. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992; 19(11): 1724–6
- Klinkhoff AV, Gertner E, Chalmers A, et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989; 16(6): 789–91
- Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25- dihydroxyvitamin D3: a pilot study. Arthritis Rheum 1990; 33(11): 1723–7
- Matucci-Cerinic M, Lotti T, Cappugi P, et al. Somatostatin treatment of psoriatic arthritis. Int J Dermatol 1988; 27(l): 56–8
- Lassus A, Dahlgren AL, Halpern MJ, et al. Effects of dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in patients with psoriasis and psoriatic arthritis. J Int Med Res 1990; 18(l): 68–73
- Kammer GM, So ter NA, Gibson DJ, et al. Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979; 9(2): 75–97